Tracking myeloma tumor DNA in peripheral blood

Mahindra, 2012, Latest advances and current challenges in the treatment of multiple myeloma, Nat Rev Clin Oncol, 9, 135, 10.1038/nrclinonc.2012.15 Kumar, 2008, Improved survival in multiple myeloma and the impact of novel therapies, Blood, 111, 2516, 10.1182/blood-2007-10-116129 Keats, 2012, Clonal competition with alternating dominance in multiple myeloma, Blood, 120, 1067, 10.1182/blood-2012-01-405985 Lohr, 2014, Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy, Cancer Cell, 25, 91, 10.1016/j.ccr.2013.12.015 Bolli, 2014, Heterogeneity of genomic evolution and mutational profiles in multiple myeloma, Nat Commun, 5, 2997, 10.1038/ncomms3997 Bergsagel, 2005, Molecular pathogenesis and a consequent classification of multiple myeloma, J Clin Oncol Off J Am Soc Clin Oncol, 23, 6333, 10.1200/JCO.2005.05.021 Chapman, 2011, Initial genome sequencing and analysis of multiple myeloma, Nature, 471, 467, 10.1038/nature09837 Morgan, 2012, The genetic architecture of multiple myeloma, Nat Rev Cancer, 12, 335, 10.1038/nrc3257 Avet-Loiseau, 2009, Prognostic significance of copy-number alterations in multiple myeloma, J Clin Oncol Off J Am Soc Clin Oncol, 27, 4585, 10.1200/JCO.2008.20.6136 Andrulis, 2013, Targeting the BRAF V600E mutation in multiple myeloma, Cancer Discov, 3, 862, 10.1158/2159-8290.CD-13-0014 Carrasco, 2006, High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients, Cancer Cell, 9, 313, 10.1016/j.ccr.2006.03.019 Raab, 2016, Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition, Blood, 127, 2155, 10.1182/blood-2015-12-686782 Rasche, 2017, Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing, Nat Commun, 8, 268, 10.1038/s41467-017-00296-y Mandel, 1948, [Not available], C R Seances Soc Biol Fil, 142, 241 Scherer, 2017, High-throughput sequencing for noninvasive disease detection in hematologic malignancies, Blood, 130, 440, 10.1182/blood-2017-03-735639 Diehl, 2008, Circulating mutant DNA to assess tumor dynamics, Nat Med, 14, 985, 10.1038/nm.1789 Hindson, 2011, High-throughput droplet digital PCR system for absolute quantitation of DNA copy number, Anal Chem, 83, 8604, 10.1021/ac202028g Adalsteinsson, 2017, Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors, Nat Commun, 8, 10.1038/s41467-017-00965-y Leary, 2010, Development of personalized tumor biomarkers using massively parallel sequencing, Sci Transl Med, 2, 10.1126/scitranslmed.3000702 Murtaza, 2013, Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA, Nature, 497, 108, 10.1038/nature12065 Kis, 2017, Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates, Nat Commun, 8, 15086, 10.1038/ncomms15086 Mithraprabhu, 2017, Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma, Leukemia, 31, 1695, 10.1038/leu.2016.366 Mithraprabhu, 2018, Circulating tumour DNA analysis for tumour genome characterisation and monitoring disease burden in extramedullary multiple myeloma, Int J Mol Sci, 19, 10.3390/ijms19071858 Mithraprabhu, 2019, Monitoring tumour burden and therapeutic response through analysis of circulating tumour DNA and extracellular RNA in multiple myeloma patients, Leukemia, 33, 2022, 10.1038/s41375-019-0469-x Manier, 2018, Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma, Nat Commun, 9, 1691, 10.1038/s41467-018-04001-5 Oberle, 2017, Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA, Haematologica, 102, 1105, 10.3324/haematol.2016.161414 Guo, 2018, Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing, Leukemia, 32, 1838, 10.1038/s41375-018-0115-z Gerber, 2018, Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias, Haematologica, 103, e245, 10.3324/haematol.2017.184358 Biancon, 2018, Noninvasive molecular monitoring in multiple myeloma patients using cell-free tumor DNA: a pilot study, J Mol Diagn JMD, 20, 859, 10.1016/j.jmoldx.2018.07.006 Rustad, 2017, Monitoring multiple myeloma by quantification of recurrent mutations in serum, Haematologica, 102, 1266, 10.3324/haematol.2016.160564 Alidousty, 2017, Comparison of blood collection tubes from three different manufacturers for the collection of cell-free DNA for liquid biopsy mutation testing, J Mol Diagn JMD, 19, 801, 10.1016/j.jmoldx.2017.06.004 Mithraprabhu, 2018, Analysis of circulating tumor DNA, Methods Mol Biol Clifton NJ, 1792, 129, 10.1007/978-1-4939-7865-6_9 Leon, 1977, Free DNA in the serum of cancer patients and the effect of therapy, Cancer Res, 37, 646 Corcoran, 2019, Cell-free DNA analysis in cancer, N Engl J Med, 380, 501, 10.1056/NEJMc1816154 Gai, 2019, Epigenetic biomarkers in cell-free DNA and applications in liquid biopsy, Genes, 10, 10.3390/genes10010032 Shamay, 2012, CpG methylation as a tool to characterize cell-free Kaposi sarcoma herpesvirus DNA, J Infect Dis, 205, 1095, 10.1093/infdis/jis032 Kortuem, 2016, Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients, Blood Canc J, 6, e397, 10.1038/bcj.2016.1 Kortüm, 2015, Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M(3)P), Ann Hematol, 94, 1205, 10.1007/s00277-015-2344-9 Chawla, 2015, Clinical course and prognosis of non-secretory multiple myeloma, Eur J Haematol, 10.1111/ejh.12478 Dupuis, 2016, Non-secretory multiple myeloma: from biology to clinical management, OncoTargets Ther, 9, 7583, 10.2147/OTT.S122241 Mills, 2017, High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma, Blood Canc J, 7 Paiva, 2012, High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma, Blood, 119, 687, 10.1182/blood-2011-07-370460 Flores-Montero, 2017, Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma, Leukemia, 31, 2094, 10.1038/leu.2017.29 Rawstron, 2015, Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction, Blood, 125, 10.1182/blood-2014-07-590166 Lohr, 2016, Genetic interrogation of circulating multiple myeloma cells at single-cell resolution, Sci Transl Med, 8, 10.1126/scitranslmed.aac7037 Mazzotti, 2018, Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow, Blood Adv, 2, 2811, 10.1182/bloodadvances.2018025197 Bai, 2016, High applicability of ASO-RQPCR for detection of minimal residual disease in multiple myeloma by entirely patient-specific primers/probes, J Hematol Oncol, 9, 107, 10.1186/s13045-016-0336-4 Bhang, 2015, Studying clonal dynamics in response to cancer therapy using high-complexity barcoding, Nat Med, 21, 440, 10.1038/nm.3841 Diamandis, 2017, Can circulating tumor DNA be used for direct and early stage cancer detection?, F1000Research, 6, 2129, 10.12688/f1000research.13440.1 Cohen, 2018, Detection and localization of surgically resectable cancers with a multi-analyte blood test, Science, 359, 926, 10.1126/science.aar3247 Shain, 2015, The genetic evolution of melanoma from precursor lesions, N Engl J Med, 373, 1926, 10.1056/NEJMoa1502583 Steensma, 2015, Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes, Blood, 126, 9, 10.1182/blood-2015-03-631747 Mishima, 2017, The mutational landscape of circulating tumor cells in multiple myeloma, Cell Rep, 19, 218, 10.1016/j.celrep.2017.03.025 Kubiczkova, 2014, Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance, Haematologica, 99, 511, 10.3324/haematol.2013.093500 Wang, 2015, Aberrant levels of miRNAs in bone marrow microenvironment and peripheral blood of myeloma patients and disease progression, J Mol Diagn JMD, 17, 669, 10.1016/j.jmoldx.2015.06.006 Navarro, 2015, A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma, Oncotarget, 6, 1874, 10.18632/oncotarget.2761 Lionetti, 2013, Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia, Clin Canc Res Off J Am Assoc Canc Res, 19, 3130, 10.1158/1078-0432.CCR-12-2043 Paiva, 2013, Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile, Blood, 122, 3591, 10.1182/blood-2013-06-510453 Baughn, 2017, Phenotypic and functional characterization of a bortezomib-resistant multiple myeloma cell line by flow and mass cytometry, Leuk Lymphoma, 58, 1931, 10.1080/10428194.2016.1266621 Waldschmidt, 2018, Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease, Semin Hematol, 55, 33, 10.1053/j.seminhematol.2018.02.010